Gynaecomastia is the enlargement of breast tissue in males, caused by a shift in the balance between oestrogen and androgen activity in the body. It can affect one or both sides of the chest, and it is far more common than most people assume, showing up in roughly half of adolescent boys during puberty and in a substantial share of older men as well.1Europe PMC. Endocrine Hormones and Their Impact on Pubertal Gynecomastia The causes range from completely normal hormonal fluctuations to medications, liver disease, and rare tumours, which means a swollen chest can be a harmless phase or a signal worth investigating.
Why It Happens
Every male body produces some oestrogen alongside testosterone. Breast tissue grows when the ratio tips toward oestrogen, either because oestrogen rises, testosterone drops, or both happen at once. During puberty, oestrogen levels climb before testosterone catches up, and that temporary mismatch is enough to stimulate breast gland growth in many boys. In the large majority of cases, roughly three out of four to nine out of ten adolescents, the tissue shrinks on its own within one to three years once the hormonal balance settles.2PubMed Central. Management of Adolescent Gynecomastia: An Update
The same basic mechanism explains gynaecomastia in older men. Testosterone production gradually declines with age while body fat, which converts androgens into oestrogen through an enzyme called aromatase, tends to increase. The net effect is a shift in the oestrogen-to-testosterone ratio that can trigger breast tissue growth decades after puberty. Conditions that lower testosterone more abruptly, such as kidney failure, certain genetic conditions, or an underactive thyroid, can accelerate the process at any age.
Medications and Substances That Trigger It
Drug-induced gynaecomastia is one of the most common non-physiological causes, and the list of medications implicated is long. Spironolactone, a blood-pressure and fluid-retention drug often prescribed for heart failure, is one of the best-documented culprits, particularly at higher doses. The exact mechanism is still debated, but research suggests spironolactone shifts the functional oestrogen-to-testosterone ratio in a way that stimulates breast tissue.3PubMed Central. Gynecomastia and drugs: a critical evaluation of the literature Other common offenders include certain anti-androgens used in prostate cancer treatment, some antipsychotics that raise prolactin levels, and proton pump inhibitors used for acid reflux. In a large review of drug-related cases, about four out of five patients reported breast pain or tenderness as their first symptom, often before noticing a visible change in size.
Anabolic steroids deserve their own mention because their connection to gynaecomastia catches many users off guard. You might expect that flooding the body with synthetic testosterone would push the hormonal balance away from oestrogen, but the opposite often happens. The body converts excess androgens into oestrogen-like compounds through aromatisation, and the resulting surge in oestrogenic activity can trigger significant breast growth.4PubMed Central. The Burden of Anabolic Androgenic Steroid-Induced Gynecomastia Steroid-induced gynaecomastia tends to be more stubborn than the pubertal variety, partly because users often cycle multiple compounds and the tissue has more time to become fibrotic.
Environmental Oestrogens and Everyday Products
One of the more surprising findings in gynaecomastia research involves lavender and tea tree oils. A study in the New England Journal of Medicine described three prepubertal boys who developed breast tissue while regularly using skin products containing these oils. Once they stopped using the products, the breast growth resolved. Lab testing on human cell lines showed that both oils have oestrogenic and anti-androgenic activity, meaning they mimic oestrogen and block testosterone at the same time.5PubMed. Prepubertal gynecomastia linked to lavender and tea tree oils
Follow-up research broadened the picture. Additional case reports documented both girls and boys developing premature breast growth after continuous exposure to lavender-containing fragrances, with the breast tissue shrinking after the products were removed. Laboratory work identified specific chemical components within these essential oils that showed varying degrees of oestrogenic and anti-androgenic behaviour.6PubMed Central. Lavender Products Associated With Premature Thelarche and Prepubertal Gynecomastia: Case Reports and Endocrine-Disrupting Chemical Activities The researchers noted that physicians should be aware these oils have endocrine-disrupting properties and consider them when evaluating unexplained breast development in children and adults alike.7The Journal of Clinical Endocrinology & Metabolism. Lavender Products Associated With Premature Thelarche and Prepubertal Gynecomastia: Case Reports and Endocrine-Disrupting Chemical Activities This does not mean everyone who uses lavender lotion will develop breast tissue, but for individuals already hormonally susceptible, regular topical exposure appears to be a genuine risk factor.
Underlying Medical Conditions
Certain diseases create the hormonal conditions for gynaecomastia to develop. Liver cirrhosis is a classic example. The liver metabolises oestrogen, so when liver function declines, oestrogen levels tend to build up. Research comparing cirrhotic patients with healthy controls found that the ratio of total oestrogen to free testosterone was roughly four times higher in the cirrhosis group. Interestingly, however, that ratio alone did not cleanly predict which cirrhotic patients developed breast tissue and which did not, suggesting that individual breast tissue sensitivity plays a role too.8PubMed. Gynecomastia and cirrhosis of the liver
Klinefelter syndrome, a genetic condition in which males carry an extra X chromosome, is associated with particularly high rates of gynaecomastia, appearing in up to about 80% of cases.9PubMed Central. The Impact and Management of Gynaecomastia in Klinefelter Syndrome The extra chromosome leads to smaller testes, reduced testosterone production, and relatively higher oestrogen levels, all of which drive breast growth. Hyperthyroidism, chronic kidney disease, and certain pituitary disorders can also shift the hormonal balance enough to produce gynaecomastia, which is why a newly diagnosed case in an adult sometimes prompts a broader medical workup.
Rarely, a hormone-secreting tumour is the cause. Leydig cell tumours in the testes, for instance, can pump out enough oestrogen to cause visible breast enlargement. One reported case involved a 32-year-old man who had gynaecomastia for two years before a small testicular mass was finally identified. After the tumour was surgically removed with a testis-sparing approach, his hormone levels normalised and the breast tissue began to shrink.10Europe PMC. Two Years of Gynecomastia Caused by Leydig Cell Tumor Certain adrenal tumours and, even more rarely, some lung cancers can produce hormones that have a similar effect.
Pseudogynecomastia and Getting the Diagnosis Right
Not every case of a larger male chest is gynaecomastia. Pseudogynecomastia, which is the accumulation of fat beneath the nipple without any actual glandular tissue growth, looks similar from the outside but has a completely different cause and does not require the same evaluation. On physical examination, true gynaecomastia produces a firm, rubbery disc of tissue that you can feel beneath the areola, while pseudogynecomastia feels softer and more diffuse. A clinician who recognises pseudogynecomastia on exam can reassure the patient without ordering blood work or imaging.11Mayo Clinic Proceedings. Gynecomastia: Pathophysiology, Evaluation, and Management
When true gynaecomastia is confirmed and the cause is not obvious, doctors typically run hormone panels and may order imaging. European Endocrine guidelines recommend checking testosterone, oestradiol, thyroid function, liver and kidney markers, and sometimes tumour markers like hCG and alpha-fetoprotein, along with a testicular ultrasound.12PubMed. EAA clinical practice guidelines-gynecomastia evaluation and management Mammography or ultrasound of the breast itself can help characterise the tissue and, in uncertain cases, distinguish gynaecomastia from something more concerning.
Male Breast Cancer and Why Doctors Take Lumps Seriously
One reason clinicians do not simply wave away a male breast lump is that male breast cancer, though uncommon, exists and can mimic gynaecomastia in its location and initial presentation. Both tend to appear in the subareolar area. Male breast cancer typically shows up as an irregular, firm mass, sometimes with skin changes or nipple retraction, but it can occasionally look deceptively round and well-defined on imaging, which means most solid breast masses in men ultimately need a tissue sample to rule out malignancy.13PubMed. Imaging the Male Breast: Gynecomastia, Male Breast Cancer, and Beyond Men with breast cancer also tend to be diagnosed at a later stage than women, in part because neither patients nor doctors expect it. A lump that is hard, off-centre, fixed to the skin, or accompanied by bloody nipple discharge warrants urgent evaluation.
Imaging can help sort things out. On mammography, gynaecomastia appears as a subareolar opacity, and radiologists recognise three patterns. A nodular pattern corresponds to active, early-stage gynaecomastia. A branching, tree-like (dendritic) pattern suggests longer-standing, fibrosed tissue. A diffuse pattern is more often seen with external oestrogen exposure.14PubMed. Imaging in gynecomastia These patterns are useful in clinical context because they can give a clue about how long the gynaecomastia has been present and whether the tissue is still in its active, potentially reversible phase or has progressed to a largely fibrotic state.
The Psychological Weight
Gynaecomastia is technically benign, but calling it harmless misses an important dimension. Adolescent boys with gynaecomastia report significantly higher levels of social anxiety and fear of negative evaluation compared with peers without it, and those effects become more pronounced as the grade of breast enlargement increases.15PubMed. Gynecomastia in Adolescents: Impact on Mental Health and Body Image Research on pubertal gynaecomastia has found that affected boys have measurably greater internalising problems, lower self-esteem, and poorer body image than controls, with the severity tracking alongside the stage of breast development.16PubMed Central. The Relationship between Psychopathology, Self-esteem, Body Perception and Serum Sex Steroids in Pubertal Gynecomastia
In adults, the research base is thinner but points in the same direction. A review of available literature found associations between gynaecomastia and depression, anxiety, disordered eating, and body dissatisfaction.17PubMed. Gynecomastia and psychological functioning: A review of the literature Many men describe avoiding situations that require removing their shirt, such as swimming or going to the gym, and the self-consciousness can persist even after the tissue itself has resolved. This psychological burden is part of the reason some clinicians push for earlier intervention rather than simply telling a teenager to wait it out.
Medical Treatment Options
When gynaecomastia does not resolve on its own, or when it is caused by a medication that cannot easily be stopped, pharmacological treatment is an option. The drugs used most often belong to a class called selective oestrogen receptor modulators (SERMs), which block oestrogen’s effect on breast tissue. A systematic review of pharmacological treatments found that tamoxifen produced visible improvement in roughly three-quarters to over nine in ten patients, with about 40 to 78% achieving at least a 50% reduction in breast size. Raloxifene, another SERM, showed at least 50% reduction in 86 to 93% of patients. Most patients began seeing improvement after three to four months of therapy.18PubMed Central. Gynecomastia: A systematic review of pharmacological treatments
Head-to-head comparisons have been limited, but one study treating pubertal gynaecomastia with both drugs found that while some improvement was seen in 86% of the tamoxifen group and 91% of the raloxifene group, a substantially larger share of the raloxifene group achieved that 50% or greater reduction. Neither drug produced notable side effects in the patients studied.19Journal of Pediatrics. Beneficial Effects of Raloxifene and Tamoxifen in the Treatment of Pubertal Gynecomastia These medications work best when the tissue is still in its active, glandular phase. Once gynaecomastia has been present for a long time and the tissue has become predominantly fibrotic, drugs are much less effective, and surgery becomes the more realistic path.
Surgical Approaches
Surgery for gynaecomastia has evolved considerably. The most commonly performed procedure today is a skin-sparing mastectomy, often combined with liposuction. The mastectomy removes the firm glandular tissue through a small incision, typically at the edge of the areola, while liposuction addresses surrounding fatty tissue to create a smoother contour.20PubMed Central. Surgical Management of Gynecomastia: A Comprehensive Review of the Literature For larger cases with significant skin excess, a mastectomy with skin reduction may be needed, which involves more extensive incisions.
Studies evaluating the combination of liposuction and subcutaneous mastectomy report high satisfaction rates, including acceptable scarring.21PubMed. Surgical Management of Gynecomastia: Subcutaneous Mastectomy and Liposuction The combination has been recommended as a standard surgical approach for cases that need glandular tissue removed. Recovery typically involves wearing a compression garment for several weeks, and most people return to normal activity within a month, though strenuous exercise is usually restricted for about six weeks. Complications are uncommon but can include asymmetry, contour irregularities, nipple numbness, and, rarely, haematoma.
Insurance Coverage Challenges
For many patients, the biggest barrier to treatment is not the surgery itself but getting it paid for. A review of 61 insurance companies found that 38% had no well-defined policy for gynaecomastia surgery and evaluated requests individually with no clear criteria. Among the 62% that did have a defined policy, the requirements varied widely: some demanded documentation of breast size and body mass index, evidence that symptoms had persisted for a certain duration, and proof that non-surgical treatments had been tried. Many policies would cover the tissue excision component but explicitly excluded liposuction, even though liposuction is routinely part of the standard combined procedure.22Plastic & Reconstructive Surgery. Surgical Management of Gynecomastia: A Review of the Current Insurance Coverage Criteria
The picture is even more frustrating for adolescents. Research examining insurance pre-authorisation outcomes for teenage gynaecomastia surgery found that denials were overwhelmingly driven by policy-level exclusions classifying the procedure as cosmetic, not by any clinical determination that the patient did not need it. Nearly half of denials cited a blanket cosmetic exclusion, while another 14% pointed to insufficient documentation.23Annals of Plastic Surgery. Access to Surgical Treatment of Adolescent Gynecomastia: Characterizing Insurance Barriers and Preauthorization Denial Rates The result is that many families end up paying out of pocket or simply going without treatment, despite the documented psychological impact of leaving significant gynaecomastia untreated during adolescence. Surgeons and endocrinologists have called for more standardised and clinically informed coverage criteria, but progress has been slow.
When Gynaecomastia Comes Back
Recurrence is a practical concern that does not get discussed enough. After surgical removal, the glandular tissue is gone and cannot regrow in the same way. But if the underlying hormonal driver persists, such as continued use of an offending medication, uncontrolled liver disease, or ongoing anabolic steroid use, residual tissue or surrounding fat can enlarge again, creating the appearance of recurrence. For drug-related cases, addressing the medication is as important as the surgery itself. In steroid users, recurrence rates are particularly notable because many resume use after surgery, restarting the same aromatisation process that caused the problem in the first place.
Weight gain after surgery can also create a cosmetically similar result through fat deposition, even without true glandular regrowth. This is one reason surgeons emphasise that maintaining a stable weight after the procedure helps preserve the result. True recurrence of glandular tissue from the same initial cause is uncommon when the underlying factor has been corrected and the surgery was thorough.
What Hormonal Blood Work Actually Tells You
One finding that surprises many patients is that their hormone levels may come back completely normal despite having obvious breast tissue. In a large review of drug-induced cases, hormone profiles were within the normal reference range in about 80% of cases tested.24PubMed Central. Gynecomastia and drugs: a critical evaluation of the literature This does not mean the hormones are irrelevant. It means that the ratio and timing of hormonal exposure matter more than a single snapshot, and that breast tissue sensitivity varies from person to person. A man whose blood testosterone and oestrogen are both within the “normal” range might still have breast tissue that responded to a transient dip in testosterone months earlier, especially if his tissue is more sensitive to oestrogenic stimulation than average.
The cirrhosis data make the same point from a different angle: even among patients with clearly abnormal oestrogen-to-testosterone ratios, not everyone develops gynaecomastia, which suggests breast tissue sensitivity is a major wildcard.25PubMed. Gynecomastia and cirrhosis of the liver For this reason, a normal blood panel does not rule out a hormonal cause, and an abnormal one does not guarantee symptoms. The workup is still worth doing because it can catch treatable conditions like thyroid dysfunction or a hormone-secreting tumour, but patients should be prepared for the possibility that all their numbers look fine and the answer is simply that their breast tissue was more responsive than average to a normal hormonal fluctuation.